ARCHIVES

Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products.

This article is from The Cancer Letter archive.

Vol. 31 No. 16 | April 22, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: White House Appoints Six to NCAB; Calabrisi To Succeed Korn As Chairman; 2 Spaces Vacant

January 25, 1991

HCFA Firm Against Reimbursement For Patients In Clinical Trials, Lasagna Committee Hears

March 24, 1989

In Vote Against Tarceva As Maintenance, ODAC Seeks Stronger Survival Benefit

December 18, 2009

In Brief: Appropriations Bill Markups Due This Month, With Increases Seen For NCI, NIH, And AIDS

July 3, 1987

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

December 27, 2002

Clearinghouse Opens With Predictable Controversy; Brown Urges ‘Open Minds’

November 12, 1976